Riskpilot← Back to searchSign inGet full accessGYNOCOR AB
ABActiveOrg 5567318885Kung Oskars Väg 7 BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20072 employees
Revenue 2025
SEK 3,4M
+20% vs 2024
EBITDA margin
50.6%
+53% vs 2024
Equity ratio
49.9%
Financial strength
Net profit 2025
SEK 900K
+185% vs 2024
| Revenue | SEK 3,4M | +20% |
| EBITDA | SEK 1,7M | +53% |
| Net profit | SEK 900K | +185% |
| Total assets | SEK 3,5M | +17% |
| Equity | SEK 1,7M | +30% |
| Employees | 2 | — |
Legal name
GYNOCOR AB
Org number
5567318885
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18 juni 2007
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva sjukvård, forskning samt konsult- och föreläsningsverksamhet inom det medicinska området och därmed förenlig verksamhet.
Address
Kung Oskars Väg 7 B
Email
thunelllouise@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 949 | 3 996 | 3 291 | 2 804 | 3 368 |
| Staff expenses | — | — | −1 596 | −1 688 | −1 664 |
| EBITDA | 1 438 | 1 533 | 1 695 | 1 116 | 1 703 |
| Depreciation & amort. | −501 | −503 | −503 | −517 | −311 |
| EBIT | 937 | 1 030 | 1 192 | 600 | 1 393 |
| Net financials | −90 | −78 | −69 | −38 | −7 |
| Profit before tax | 610 | 812 | 946 | 408 | 1 145 |
| Tax | −133 | −168 | −198 | −92 | −245 |
| Net profit | 477 | 644 | 749 | 316 | 900 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 681 | 3 807 | 3 646 | 2 988 | 3 501 |
| Equity | 728 | 1 187 | 1 490 | 1 346 | 1 746 |
| Long-term debt | 1 516 | 886 | 276 | 0 | — |
| Short-term debt | 701 | 859 | 829 | 437 | 309 |
| Total debt | 2 217 | 1 745 | 1 104 | 437 | 309 |
EBITDA margin
50.6%
This company
15.8%
Market median
+220% vs market
20212025
Equity ratio
49.9%
This company
38.2%
Market median
+31% vs market
20212025
Return on equity
51.5%
This company
18.4%
Market median
+180% vs market
20212025
Net profit margin
26.7%
This company
8.1%
Market median
+230% vs market
20212025
Asset turnover
0.96×
This company
1.12×
Market median
+14% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HM | Audit | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2024 | |
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GYNOCOR AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helene Maria Hasselström | Audit | 0 companies |
| Carl Johan Scherstén | Deputy Board Member | 0 companies |
| Bengt Johan Fredrik Scherstén | Deputy Board Member | 0 companies |
| Anna Louise Thunell | Board of Directors | 0 companies |
| Anna Carolina Scherstén | Deputy Board Member | 0 companies |
| Gustav Fredrik Scherstén | Deputy Board Member | 0 companies |